Switching from sildenafil to riociguat for the treatment of PAH and inoperable CTEPH: Real-life experiences

Riociguat is a novel soluble guanylate cyclase stimulator that is approved for the treatment of patients with pulmonary arterial hypertension (PAH) and patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or persistent/recurrent CTEPH after pulmonary endarterectomy (PEA). A...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Respir Med Case Rep
Autori principali: Andersen, Asger, Korsholm, Kasper, Mellemkjær, Søren, Nielsen-Kudsk, Jens Erik
Natura: Artigo
Lingua:Inglês
Pubblicazione: Elsevier 2017
Soggetti:
Case Report
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5476463/
https://ncbi.nlm.nih.gov/pubmed/28652963
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.rmcr.2017.06.005
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi